Successful nilotinib treatment in a patient with chronic myelogenous leukemia after failure of treatment with two tyrosine kinase inhibitors due to intolerance and resistance
Affiliations- Klinika Hematologii z Oddziałem Transplantacji Szpiku, Samodzielny Publiczny Szpital Kliniczny nr 1 PUM im. prof. Tadeusza Sokołowskiego, zpital Kliniczny nr 1 PUM im. prof. Tadeusza Sokołowskiego w Szczecinie, ul. Unii Lubelskiej 1, 71–252 Szczecin, 71–252 Szczecin, Poland
open access
Abstract
Treatment with tyrosine kinase inhibitors (TKI) produces good results in patients with chronic
myelogenous leukemia (CML). However, some patients need to change the therapy due to intolerance
or resistance to TKI applied. In these situations, the possibility of 2nd generation TKI administration
allows to achieve deep molecular response (DMR) and long survival of patients. In this
paper, a case of adult patient with CML who experienced hepatic toxicity of imatinib and failure
of dasatinib treatment due to resistance is presented. Subsequently, the treatment with nilotinib
resulted in a long-term DMR.
Abstract
Treatment with tyrosine kinase inhibitors (TKI) produces good results in patients with chronic
myelogenous leukemia (CML). However, some patients need to change the therapy due to intolerance
or resistance to TKI applied. In these situations, the possibility of 2nd generation TKI administration
allows to achieve deep molecular response (DMR) and long survival of patients. In this
paper, a case of adult patient with CML who experienced hepatic toxicity of imatinib and failure
of dasatinib treatment due to resistance is presented. Subsequently, the treatment with nilotinib
resulted in a long-term DMR.
Keywords
chronic myelogenous leukemia, tyrosine kinases inhibitors, intolerance, resistance
About this articleTitle
Successful nilotinib treatment in a patient with chronic myelogenous leukemia after failure of treatment with two tyrosine kinase inhibitors due to intolerance and resistance
Journal
Hematology in Clinical Practice
Issue
Article type
Case report
Pages
4-8
Page views
250
Article views/downloads
311
DOI
10.5603/Hem.2018.0009
Keywords
chronic myelogenous leukemia
tyrosine kinases inhibitors
intolerance
resistance
Authors
Edyta Paczkowska
